<DOC>
	<DOCNO>NCT00125034</DOCNO>
	<brief_summary>This open label , randomize , control , multicenter phase II study compare 5-FU/FA + oxaliplatin ( FOLFOX-4 ) + cetuximab versus 5-FU/FA + oxaliplatin first-line treatment epidermal growth factor receptor ( EGFR ) -expressing mCRC .</brief_summary>
	<brief_title>Oxaliplatin Cetuximab First-line Treatment Metastatic Colorectal Cancer ( mCRC )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Firstline mCRC EGFR positive Bidimensional measurable index lesion Previous exposure EGFRtargeting therapy Previous oxaliplatinbased therapy Previous chemotherapy colorectal cancer except adjuvant treatment progression disease document &gt; 6 month end adjuvant treatment Radiotherapy Surgery Any investigational drug 30 day randomization Brain metastasis and/or leptomeningeal disease Acute subacute intestinal occlusion history inflammatory bowel disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>FOLFOX-4</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>First-line mCRC</keyword>
	<keyword>EGFR positive</keyword>
	<keyword>metastatic CRC</keyword>
</DOC>